After a 130% rise in its share price in the last year, the pharmaceuticals company has left the big two banks and Nice a long way behind. The share price of Teva Pharmaceutical Industries (TASE: TEVA; NYSE: TEVA) has risen by 130% in the past year. The company has thereby once more become the largest in market cap terms on the Tel Aviv Stock Exchange, overtaking technology company Nice (TASE: NICE; Nasdaq: NICE) and the big two banks, Leumi (TASE: LUMI) and Hapoalim (TASE: POLI).
Teva currently has a market cap of NIS 72 billion, leading the next largest company, Bank Leumi, by a gap of more than NIS 25 billion (54%). In fact, Teva has the second best return of the stocks on the Tel Aviv 35 Index list, outdone only by semiconductor inspection equipment company Camtek (TASE: CAMT; Nasdaq: CAMT), which has risen by 268%, borne aloft by the euphoria over AI chips. Teva is the second largest among Israeli companies traded in New York, after autotech company Mobileye (Nasdaq: MBLY).
In dollar terms, Teva has a market cap of $19.6 billion, and Mobileye $22.7 billion.
Third largest is Check Point (Nasdaq: CHKP), with a market cap of $17.7 billion, followed by Monday.com (Nasdaq: MNDY) and Nice, both on $11.
1 billion. Why Teva has taken off The rise in Teva’s share price is largely due to the company’s own efforts. It underwent far-reaching changes under its previous CEO, Kare Schultz: it cut costs, introduced efficiency measures, closed plants, laid of more than 15,000 employees.
